Table 1 Patient demographics and baseline disease characteristics (Full analysis set)
|  | Erenumab 70 mg N = 279 | Placebo N = 278 | All patients N = 557 |
|---|---|---|---|
Age (years), mean (± SD) | 41.4 (10.9) | 41.9 (10.9) | 41.7 (10.9) |
Sex, n (%) | |||
 Men | 62 (22.2) | 41 (14.7) | 103 (18.5) |
 Women | 217 (77.8) | 237 (85.3) | 454 (81.5) |
Race, n (%) | |||
 Asian | 279 (100.0) | 278 (100.0) | 557 (100.0) |
 Chinese | 206 (73.8) | 215 (77.3) | 421 (75.6) |
 Indian | 19 (6.8) | 14 (5.0) | 33 (5.9) |
 Korean | 22 (7.9) | 18 (6.5) | 40 (7.2) |
 Vietnamese | 7 (2.5) | 8 (2.9) | 15 (2.7) |
 Multipleb | 2 (0.7) | 3 (1.1) | 5 (0.9) |
Ethnicity, n (%) | |||
 Hispanic or Latino | 2 (0.7) | 0 | 2 (0.4) |
 Not Hispanic or Latino | 277 (99.3) | 277 (99.6) | 554 (99.5) |
 Not Reported | 0 | 1 (0.4) | 1 (0.2) |
BMI (kg/m2), mean (± SD) | 23.3 (4.0) c | 23.1 (4.0) | 23.2 (4.0) |
Monthly migraine days, mean (± SD) | 19.1 (5.3) | 19.3 (5.6) | 19.2 (5.4) |
Monthly headache days, mean (± SD) | 21.7 (4.2) | 22.1 (4.3) | 21.9 (4.3) |
Monthly moderate and severe headache days, mean (± SD) | 16.8 (6.3) | 17.2 (6.4) | 17.0 (6.4) |
Monthly acute headache medication use, days, mean (± SD) | 14.1 (8.3) | 14.6 (8.2) | 14.3 (8.2) |
Acute headache medication n (%) | |||
 Yes | 262 (93.9) | 266 (95.7) | 528 (94.8) |
 None | 17 (6.1) | 12 (4.3) | 29 (5.2) |
Age at onset of migraine (years), mean (± SD) | 23.3 (10.0) | 24.2 (9.6) | 23.7 (9.8) |
Disease duration of migraine with/without aura (years), mean (± SD) | 18.2 (11.9) | 17.8 (11.4) | 18.0 (11.6) |
Aura status, n (%) | |||
 Migraine with aura | 197 (70.6) | 214 (77.0) | 411 (73.8) |
 Migraine without aura | 82 (29.4) | 64 (23.0) | 146 (26.2) |
Prior preventive migraine treatment failure statusa n (%) | |||
 Yes | 83 (29.7) | 83 (29.9) | 166 (29.8) |
 No | 196 (70.3) | 195 (70.1) | 391 (70.2) |
Number of prior preventive migraine treatment category n (%) | |||
 None | 108 (38.7) | 100 (36.0) | 208 (37.3) |
 1 | 57 (20.4) | 62 (22.3) | 119 (21.4) |
 2 | 41 (14.7) | 40 (14.4) | 81 (14.5) |
 3 | 40 (14.3) | 45 (16.2) | 85 (15.3) |
 4 | 23 (8.2) | 18 (6.5) | 41 (7.4) |
 > 4 | 10 (3.6) | 13 (4.7) | 23 (4.1) |
Number of prior preventive migraine treatment failure n (%) | Â | Â | Â |
None | 199 (71.3) | 204 (73.4) | 403 (72.4) |
1 | 43 (15.4) | 46 (16.5) | 89 (16.0) |
2 | 31 (11.1) | 17 (6.1) | 48 (8.6) |
3 | 6 (2.2) | 10 (3.6) | 16 (2.9) |
 > 3 | 0 | 1 (0.4) | 1 (0.2) |
Medication overusea n (%) | |||
 Yes | 158 (56.6) | 159 (57.2) | 317 (56.9) |
 No | 121 (43.4) | 119 (42.8) | 240 (43.1) |